New immune cell therapy shows promise for Hard-to-Treat melanoma
NCT ID NCT05628883
First seen Jan 11, 2026 · Last updated Jun 18, 2026 · Updated 27 times
Summary
This early-phase study tested a new treatment called TBio-4101 for people with advanced melanoma that has not responded to standard therapies. The treatment uses a patient's own immune cells (TILs) that are collected from their tumor, multiplied in a lab, and then given back after chemotherapy. The goal was to see if this approach is safe and feasible for patients with various types of melanoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.